GlaxoSmithKline plc (NYSE:GSK) does about 2.90M shares in volume on a normal day but saw 3710498 shares change hands in Tuesday trading. The company now has a market cap of 97.41B USD and an enterprise value of about $129.93B. Its current market price is $38.96, marking a decrease of -1.62% compared to the previous close of $39.60. The 52 week high reached by this stock is $48.25 whilst the lowest price level in 52 weeks is $31.43. The script in recent trading has seen the stock touch a high of $39.35 and a low of $38.71.
GlaxoSmithKline plc (GSK) has a 20-day trading average at $40.57 and the current price is -19.25% off the 52-week high compared with 23.96% distance from its 52-week low. The 50-day simple moving average of the closing price is $40.76 and its 200-day simple moving average is $42.21. If we look at the stock’s price movements over the week, volatility stands at 1.22%, which decreases to 1.08% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 32.92 to suggest the stock is neutral.
20 analysts observing the GlaxoSmithKline plc (GSK) stock have set the 12-month price targets for the company’s shares at between $38.62 and $57.04. The consensus objective for the share price is $47.70, suggesting that the stock has a potential upside of 18.32% over the period. The median price target is 17.82% away from the current levels at $47.41.
FactSet Research has provided data showing that 20 brokerages have issued ratings for the stock. 2 analysts have rated it as a sell, while 1 advise that it is a overweight. 8 analysts have rated it as a buy and 9 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on February 12, 2020 when Shore Capital downgraded the stock to “Sell” and issued a price target of . Barclays also downgraded the stock to “Underweight” from Equal Weight on January 16, 2020 at a price target of .
The current price level is -4.23%, -4.53%, and -7.74% away from its SMA20, SMA50, and SMA200 respectively, with the GSK price moving above the 50-day SMA on September 01. GlaxoSmithKline plc (GSK) stock is down -2.94% over the week and -5.64% over the past month. Its price is -17.09% year-to-date and -8.16% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of $0.46 below consensus estimates by -$0.05. The company’s next earnings report is expected on 10/28/2020, with forecasts estimating quarterly EPS at $0.86 and $2.97 for whole year. GSK’s earnings per share are forecast to shrink by -6.00% this year and 1.30% over next year. Expected sales for next quarter are $12 billion, which analysts say will come at $46.41 billion for the current fiscal year and next year at $48.11 billion. In addition, estimates put the company’s current quarterly revenue at an average of $12.25 billion.
Its 12-month price target is $47.41. To reach the target analysts have set, the stock logically needs to grow 18.32 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $38.62, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $57.04.
Outstanding shares total 2.49B with insiders holding 0.01% of the shares and institutional holders owning 12.17% of the company’s common stock. The company has a return on investment of 14.30% and return on equity of 53.60%. The price to earnings ratio (P/E ratio) amounts to 11.10 while the forward price to earnings ratio is 12.93. The beta has a value of 0.66. Price to book ratio is 5.40 and price to sales ratio is 2.11.
According to a U.S. Securities and Exchange Commission filing, Dodge & Cox Funds – Stock Fund has reduced its position in GlaxoSmithKline plc (GSK) to 26,084,900 shares, mirroring a recent drop by -6.79%. Dodge & Cox Funds – Stock Fund dumped -1.9 million shares of GlaxoSmithKline plc common stock bringing its total worth to about $1.05 billion at the end of recent close, SEC documents show. Dodge & Cox Funds – Stock Fund isn’t the only investment manager who changed stakes and is followed by American Mutual Fund, which added 8.36 million shares to end up with 15,536,335 shares worth $626.43 million. Washington Mutual Investors Fund cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.30% position in GlaxoSmithKline plc thanks to 7.55 million shares amounting to $304.3 million.